Key Takeaways
- Shares of HIMS rose approximately 13% on April 16, 2026, after the FDA announced plans to review peptide regulations
- The FDA set July 23-24 meetings to assess multiple peptides for potential inclusion on the 503A Bulks List
- BofA Securities increased its price target from $21 to $25 while keeping its Neutral rating unchanged
- Analysts view this development as a modest positive for the long term, though without immediate earnings implications
- Company insiders have offloaded roughly $3.4 million in shares over the last three months with no insider buying activity
Hims & Hers Health (HIMS) experienced a stock surge of up to 13.72% on April 16, 2026, triggered by the FDA’s announcement that it will convene advisory committee sessions to assess various wellness peptides that currently face restrictions under existing regulatory guidelines.
Hims & Hers Health, Inc., HIMS
The regulatory agency released a formal notice establishing Pharmacy Compounding Advisory Committee sessions scheduled for July 23 and 24. These meetings will examine several peptide-based bulk drug substances for potential addition to the 503A Bulks List. This represents an initial procedural action rather than a final regulatory approval.
Public statements from RFK Jr. regarding potential FDA regulatory modifications contributed to increased investor optimism. The FDA is considering removing restrictions on as many as 12 peptides, with evaluation sessions planned extending through February 2027.
The stock had demonstrated upward momentum prior to this announcement. During the previous week, HIMS gained approximately 25%, based on InvestingPro’s tracking data.
BofA Increases Valuation Target
BofA Securities adjusted its outlook by raising the price target on HIMS from $21 to $25, though the firm maintained its Neutral rating. The investment bank elevated its target valuation multiple to roughly 25.5 times from 21.5 times, attributing the change to elevated peer valuations and potential peptide opportunities.
BofA highlighted that this development might enable the company to redirect its existing GLP-1 compounding infrastructure toward alternative peptides. This consideration holds significance because HIMS has invested substantially in GLP-1 infrastructure following previous FDA compounding limitations.
The investment firm maintained a measured perspective in its assessment. It characterized the development as “an initial small step” and indicated no anticipated near-term modifications to earnings projections unless the FDA proceeds with a definitive regulatory decision.
The FDA also emphasized that the majority of substances under consideration continue to present potential safety concerns under current regulatory guidance.
Additional HIMS Developments
HIMS has recently expanded its offerings to include Novo Nordisk’s FDA-approved GLP-1 medications, adding Wegovy in both injectable and oral formulations. The oral Wegovy represents the sole FDA-approved GLP-1 weight loss pill on the market.
The platform will additionally provide Ozempic injection pens, which carry FDA approval exclusively for Type 2 diabetes treatment.
The GLP-1 market has seen intensifying competitive dynamics. Amazon Pharmacy recently launched same-day delivery service for Eli Lilly’s newly approved GLP-1 medication Foundayo, creating competitive challenges for both Novo Nordisk and HIMS.
Regarding insider activity, CFO Oluyemi Okupe submitted paperwork to divest shares valued at roughly $4.9 million. During the last three months, company insiders have collectively sold approximately $3.4 million worth of shares, with zero insider purchases documented.
HIMS currently trades at a price-to-earnings ratio in the 45-47x range. InvestingPro’s assessment indicates the stock appears overvalued compared to its Fair Value calculation. The company maintains a market capitalization of approximately $5.54 billion and serves more than 2 million subscribers.
BofA’s EBITDA projection for 2026 stands roughly 21% beneath the Wall Street consensus estimate, a discrepancy the firm has noted in previous research reports.
